What is the treatment for hyperammonemia due to Non-Alcoholic Steatohepatitis (NASH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Hyperammonemia Due to NASH

For hyperammonemia in the context of NASH, immediately stop all protein intake, provide IV glucose (8-10 mg/kg/min) and lipids to prevent catabolism, initiate ammonia-scavenging agents (sodium benzoate and sodium phenylacetate), and prepare for urgent hemodialysis if ammonia levels exceed 300 μmol/L or if moderate-to-severe encephalopathy develops. 1, 2, 3

Understanding NASH-Related Hyperammonemia

NASH causes hyperammonemia through a distinct mechanism compared to cirrhosis:

  • Urea cycle dysfunction occurs at the pre-cirrhotic stage in NASH patients, with reduced expression and activity of urea cycle enzymes leading to impaired ammonia detoxification capacity 4
  • This functional reduction in ureagenesis results in hyperammonemia even before cirrhosis develops, distinguishing NASH from other liver diseases 4
  • Ammonia directly activates hepatic stellate cells, promoting fibrosis progression and worsening the underlying NASH pathology 4

Immediate Management Protocol

Stop Nitrogen Load and Prevent Catabolism

  • Discontinue all oral protein intake immediately to reduce nitrogen load and prevent further ammonia production 1, 2
  • Provide adequate calories (≥100 kcal/kg daily) through IV glucose infusion at 8-10 mg/kg/min 1, 2
  • Add IV lipids starting at 0.5 g/kg daily, up to 3 g/kg daily, to prevent protein catabolism which drives further ammonia generation 1, 2

Critical pitfall: Do not extend protein restriction beyond 48 hours, as prolonged restriction paradoxically promotes catabolism and worsens hyperammonemia 2

Pharmacological Ammonia-Scavenging Therapy

Initiate IV nitrogen scavengers immediately:

  • Sodium benzoate dosing: 1, 3

    • For patients <20 kg: 250 mg/kg IV over 90 minutes as loading dose, then same dose as continuous maintenance over 24 hours
    • For patients >20 kg: 5.5 g/m² IV over 90 minutes as loading dose, then same dose as continuous maintenance over 24 hours
  • Sodium phenylacetate dosing (same as sodium benzoate): 1, 3

    • For patients <20 kg: 250 mg/kg IV over 90 minutes, then continuous maintenance
    • For patients >20 kg: 5.5 g/m² IV over 90 minutes, then continuous maintenance
  • L-arginine hydrochloride: 200 mg/kg (for <20 kg) or 4 g/m² (for >20 kg) may be considered, though this is primarily indicated for urea cycle disorders rather than NASH-related hyperammonemia 1, 3

Administration note: These agents must be diluted in sterile 10% dextrose and administered via central venous catheter to avoid burns from peripheral administration 3

Kidney Replacement Therapy Decision Algorithm

Indications for Urgent Dialysis

Consider hemodialysis or continuous kidney replacement therapy when: 1, 2, 3

  • Ammonia levels exceed 300 μmol/L
  • Moderate-to-severe encephalopathy develops (altered mental status, confusion, lethargy)
  • Seizures occur
  • Neurological status deteriorates despite medical management
  • Ammonia levels remain persistently elevated after 3-4 hours of ammonia-scavenging therapy

Choice of Dialysis Modality

  • High-dose continuous venovenous hemodialysis (CVVHD) is first-line when available, with blood flow rate 30-50 mL/min and dialysis fluid flow rate/Qb ratio >1.5 1
  • Intermittent hemodialysis achieves the most rapid ammonia clearance, reducing levels by 50% within 1-3 hours, making it ideal for rapidly deteriorating patients 5, 1, 3
  • Hybrid therapy (HD followed by CVVHD) is recommended for ammonia levels >1,500 μmol/L to achieve rapid initial reduction while preventing rebound hyperammonemia 5

Critical consideration: The duration of hyperammonemic coma before dialysis initiation is the most important prognostic factor for neurological outcomes, not the rate of ammonia clearance itself 1, 6

Monitoring During Treatment

Check the following parameters every 3-4 hours until ammonia normalizes: 1, 2

  • Plasma ammonia levels
  • Neurological status (Glasgow Coma Scale, level of consciousness)
  • Electrolytes, particularly during CKRT
  • Blood glucose
  • Venous or arterial blood gases

Sample collection pitfall: Ammonia samples must be collected from free-flowing venous or arterial blood, transported on ice, and processed within 15 minutes to avoid falsely elevated results 1

Protein Reintroduction

Once ammonia levels decrease below 200 μmol/L on two consecutive hourly measurements: 5, 1

  • Gradually reintroduce protein starting at 0.25 g/kg daily
  • Increase incrementally up to 1.5 g/kg daily over 48 hours
  • Continue ammonia-scavenging agents during this transition to prevent rebound

Transition to Oral Management

After ammonia normalization and neurological improvement: 3

  • Transition to oral sodium phenylbutyrate for long-term ammonia control
  • Implement dietary protein restriction tailored to maintain ammonia in normal range
  • Continue nutritional supplementation to prevent catabolism

Key Clinical Pitfalls to Avoid

  • Do not delay treatment waiting for confirmatory testing – initiate therapy immediately based on clinical suspicion and elevated ammonia 2
  • Do not use rigid ammonia thresholds alone – the patient's evolving clinical status (encephalopathy severity, neurological deterioration) should guide treatment intensity 1, 2
  • Do not continue protein intake during acute hyperammonemia, as this directly contradicts the fundamental principle of reducing nitrogen load 6
  • Do not restrict protein beyond 48 hours without reintroduction, as this triggers catabolism and paradoxically worsens hyperammonemia 2
  • Recognize that respiratory alkalosis is an early distinguishing feature of hyperammonemia that differentiates it from other causes of encephalopathy 6

References

Guideline

Management of Hyperammonemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Non-Cirrhotic Hyperammonemic Encephalopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hyperammonemia Causes and Mechanisms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.